Chen Shanquan, Cardinal Rudolf N, Auckland Kathryn, Gräf Stefan, O'Brien John T, Underwood Benjamin R
Department of Psychiatry, University of Cambridge, Cambridge, UK.
Cambridgeshire and Peterborough NHS Foundation Trust, UK.
J Alzheimers Dis. 2023;92(1):295-309. doi: 10.3233/JAD-221093.
Persisting symptoms and increased mortality after SARS-CoV-2 infection has been described in COVID-19 survivors.
We examined longer-term mortality in patients with dementia and SARS-CoV-2 infection.
A retrospective matched case-control study of 165 patients with dementia who survived an acute hospital admission with COVID-19 infection, and 1325 patients with dementia who survived a hospital admission but without SARS-CoV-2 infection. Potential risk factors investigated included socio-demographic factors, clinical features, and results of investigations. Data were fitted using a Cox proportional hazard model.
Compared to patients with dementia but without SARS-CoV-2 infection, people with dementia and SARS-CoV-2 infection had a 4.4-fold risk of death (adjusted hazard ratio [aHR] = 4.44, 95% confidence interval [CI] 3.13-6.30) even beyond the acute phase of infection. This excess mortality could be seen up to 125 days after initial recovery but was not elevated beyond this time. Risk factors for COVID-19-associated mortality included prescription of antipsychotics (aHR = 3.06, 95% CI 1.40-6.69) and benzodiazepines (aHR = 3.00, 95% CI 1.28-7.03). Abnormalities on investigation associated with increased mortality included high white cell count (aHR = 1.21, 95% CI 1.04-1.39), higher absolute neutrophil count (aHR = 1.28, 95% CI 1.12-1.46), higher C-reactive protein (aHR = 1.01, 95% CI 1.00-1.02), higher serum sodium (aHR = 1.09, 95% CI 1.01-1.19), and higher ionized calcium (aHR = 1.03, 95% CI 1.00-1.06). The post-acute COVID mortality could be modeled for the first 120 days after recovery with a balanced accuracy of 87.2%.
We found an increased mortality in patients with dementia beyond the acute phase of illness. We identified several investigation results associated with increased mortality, and increased mortality in patients prescribed antipsychotics or benzodiazepines.
新冠病毒感染幸存者中出现了持续症状和死亡率增加的情况。
我们研究了患有痴呆症且感染新冠病毒患者的长期死亡率。
一项回顾性匹配病例对照研究,研究对象为165名因新冠病毒感染而急性入院存活的痴呆症患者,以及1325名入院存活但未感染新冠病毒的痴呆症患者。调查的潜在风险因素包括社会人口统计学因素、临床特征和检查结果。数据采用Cox比例风险模型进行拟合。
与未感染新冠病毒的痴呆症患者相比,感染新冠病毒的痴呆症患者死亡风险高出4.4倍(调整后风险比[aHR]=4.44,95%置信区间[CI]3.13 - 6.30),甚至在感染急性期过后也是如此。这种额外的死亡率在初次康复后长达125天内都可见,但在此之后并未升高。与新冠病毒相关死亡率的风险因素包括使用抗精神病药物(aHR=3.06,95%CI 1.40 - 6.69)和苯二氮䓬类药物(aHR=3.00,95%CI 1.28 - 7.03)。与死亡率增加相关的检查异常包括白细胞计数升高(aHR=1.21,95%CI 1.04 - 1.39)、绝对中性粒细胞计数升高(aHR=1.28,95%CI 1.12 - 1.46)、C反应蛋白升高(aHR=1.01,95%CI 1.00 - 1.02)、血清钠升高(aHR=1.09,95%CI 1.01 - 1.19)和离子钙升高(aHR=1.03,95%CI 1.00 - 1.06)。康复后前120天的新冠病毒感染后死亡率可以进行建模,平衡准确率为87.2%。
我们发现痴呆症患者在疾病急性期过后死亡率增加。我们确定了几个与死亡率增加相关的检查结果,以及使用抗精神病药物或苯二氮䓬类药物患者的死亡率增加。